Learn more about the impact of perinatal depression on child neurodevelopment, new rapid-acting treatments for PPD, and new data reshaping how we treat menopausal symptoms.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
This week’s list spans antidepressant safety, benefits of psychotropic medication continuation on postpartum self-harm risk, anti-seizure medications and congenital malformations, and new approaches to PPD screening.
This week’s roundup covers prenatal SARS-CoV-2 exposure and child neurodevelopment, cannabis use in pregnancy and related risks, and estradiol-linked mood changes during menopause.
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
With ketamine and esketamine increasingly used to treat depression, especially in women of reproductive age, this study reveals important gaps in care, including inconsistencies in pregnancy testing, informed consent, and contraception practices among ketamine clinics in the United States.Â
Further studies are needed to determine whether ketamine and esketamine are effective for the treatment of postpartum depression.
Intravenous ketamine or esketamine given at the time of cesarean delivery reduced risk for postpartum depression; predictive models are needed to determine which women are most likely to benefit from this intervention.
I am taking care of a patient with a history of severe recurrent depression. Although she did relatively well during pregnancy on duloxetine 120 mg, she experienced recurrent, severe depressive symptoms after giving birth. [...]
